title: [Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].
abstract: A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83% of the control group and 63% of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12% of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×10(6)/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×10(6) cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×10(6) cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.
authors: Department of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan.
authors: Tsuyoshi
authors: T
authors: Muta
authors: Toshihiro
authors: T
authors: Miyamoto
authors: Tomoaki
authors: T
authors: Fujisaki
authors: Yuju
authors: Y
authors: Ohno
authors: Tomohiko
authors: T
authors: Kamimura
authors: Tomoko
authors: T
authors: Henzan
authors: Koji
authors: K
authors: Kato
authors: Katsuto
authors: K
authors: Takenaka
authors: Hiromi
authors: H
authors: Iwasaki
authors: Tetsuya
authors: T
authors: Eto
authors: Yasushi
authors: Y
authors: Takamatsu
authors: Takanori
authors: T
authors: Teshima
authors: Koichi
authors: K
authors: Akashi
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D060828:Induction Chemotherapy / Q000941:ethics*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D016179:Granulocyte Colony-Stimulating Factor; D000069286:Bortezomib